Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. Incyte beat analysts’ revenue expectations by 5.2% last ...

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...

Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago. These figures ...

Technically, INCY is currently below its 30-week EMA, with short-term bearish momentum but long-term bullish momentum, making it a cautious buy. Volume analysis shows neutral institutional ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed yesterday at $68.30. Leverage the power of TipRanks ...

I first met Wincy Ong in the buzzing world of advertising and PR, a place where creativity and storytelling intertwine with the art of persuasion. Back then, we were just two professionals navigating ...

Deep-pocketed investors have adopted a bullish approach towards Incyte INCY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...